EBERHARD CRAIG A 4
4 · AMYLIN PHARMACEUTICALS INC · Filed Mar 6, 2009
Insider Transaction Report
Form 4
EBERHARD CRAIG A
VP Sales
Transactions
- Award
Common Stock
2009-03-04+2,550→ 3,455 total(indirect: by ESOP) - Award
Incentive Stock Option (right to buy)
2009-03-04+4,687→ 4,687 totalExercise: $9.02Exp: 2016-03-04→ Common Stock (4,687 underlying) - Award
Non-Qualified Stock Option (right to buy)
2009-03-04+10,000→ 10,000 totalExercise: $9.02Exp: 2016-03-04→ Common Stock (10,000 underlying) - Award
Non-Qualified Stock Option (right to buy)
2009-03-04+10,313→ 20,313 totalExercise: $9.02Exp: 2016-03-04→ Common Stock (10,313 underlying)
Holdings
- 24,464
Common Stock
Footnotes (3)
- [F1]These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment.
- [F2]25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant.
- [F3]These performance-based options fully vest only if Amylin's drug candidate exenatide once weekly is approved for commercial use by year-end 2010. If this business objective is not attained by December 31, 2010, the options will be forfeited.